lotiglipron
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 5, 2019 (NCT04148209)
Timeline
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]1(c2ccc(Cl)cn2)Oc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)c2O1- Mol. weight
- 575.07 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314631 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05788328 | Phase 1 | Mar 27, 2023 | Pfizer |
| NCT05745701 | Phase 1 | Feb 22, 2023 | Pfizer |
| NCT05671653 | Phase 1 | Jan 19, 2023 | Pfizer |
| NCT05677867 | Phase 1 | Jan 18, 2023 | Pfizer |
| NCT05652647 | Phase 1 | Dec 15, 2022 | Pfizer |
| NCT05579977 | Phase 2 | Oct 27, 2022 | Pfizer |
| NCT05510245 | Phase 1 | Aug 29, 2022 | Pfizer |
| NCT05478603 | Phase 1 | Aug 1, 2022 | Pfizer |
| NCT05158244 | Phase 1 | Dec 15, 2021 | Pfizer |
| NCT04305587 | Phase 1 | Mar 16, 2020 | Pfizer |
| NCT04148209 | Phase 1 | Nov 5, 2019 | Pfizer |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 11 | 11 | 2 | 2019 |
1 organizations
Page 1 / 1